Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

Clinical Neurophysiology

Volumn 126, Issue 1, 2015, Pages 165-169

  Landi, D ^a   Vollaro, S ^a   Pellegrino, G ^a   Mulas, D ^a   Ghazaryan, A ^a   Falato, E ^a   Pasqualetti, P ^a   Rossini, P M ^a   Filippi, M M ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Fingolimod; Glutamate; Intracortical facilitation; Motor cortex; Multiple sclerosis; Transcranial magnetic stimulation

Indexed keywords

FINGOLIMOD; GLUTAMIC ACID; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFECT; EVOKED MUSCLE RESPONSE; FACILITATION; FEMALE; HUMAN; IN VIVO STUDY; MALE; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; NERVE EXCITABILITY; NEUROMODULATION; NEUROTRANSMISSION; PRIMARY MOTOR CORTEX; PROSPECTIVE STUDY; STIMULUS RESPONSE; TRANSCRANIAL MAGNETIC STIMULATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; MIDDLE AGED; MOTOR CORTEX; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADMINISTRATION, ORAL; ADULT; ANIMALS; EVOKED POTENTIALS, MOTOR; FEMALE; GLUTAMIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MOTOR CORTEX; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; PROSPECTIVE STUDIES; SPHINGOSINE; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84917741469     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2014.05.031     Document Type: Article

References (48)

1. Caramia M.D., Palmieri M.G., Desiato M.T., Boffa L., Galizia P., Rossini P.M., et al. Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation. Clin Neurophysiol 2004, 115:956-965.
2. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009, 29:3442-3452.
3. Centonze D., Muzio L., Rossi S., Furlan R., Bernardi G., Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 2009, 17:1083-1091.
4. 1, plays a prominent but not exclusive role in enhancing the excitability of sensory neurons. J Neurophysiol 2010, 104:2741-2748.
5. Chun J., Hartung H.-P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010, 33:91-101.
6. Conte A., Lenzi D., Frasca V., Gilio F., Giacomelli E., Gabriele M., et al. Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis. J Neurol 2009, 256:933-938.
7. Geurts J.J.G., Wolswijk G., Bö L., van der Valk P., Polman C.H., Troost D., et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain J Neurol 2003, 126:1755-1766.
8. Geurts J.J.G., Wolswijk G., Bö L., Redeker S., Ramkema M., Troost D., et al. Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions. J Neuroimmunol 2005, 158:182-190.
9. Groves A., Kihara Y., Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013, 328:9-18.
10. Hanley J.A., Negassa A., deB Edwardes M.D., Forrester J.E. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003, 157:364-375.
11. Kajimoto T., Okada T., Yu H., Goparaju S.K., Jahangeer S., Nakamura S. Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol Cell Biol 2007, 27:3429-3440.
12. Kanno T., Nishizaki T. Endogenous sphingosine 1-phosphate regulates spontaneous glutamate release from mossy fiber terminals via S1P(3) receptors. Life Sci 2011, 89:137-140.
13. Kim K., Lee S.-G., Kegelman T.P., Su Z.-Z., Das S.K., Dash R., et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011, 226:2484-2493.
14. Kobayashi M., Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol 2003, 2:145-156.
15. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., et al. Corticocortical inhibition in human motor cortex. J Physiol 1993, 471:501-519.
16. Lai A.Y., Swayze R.D., El-Husseini A., Song C. Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J Neuroimmunol 2006, 175:97-106.
17. Miron V.E., Schubart A., Antel J.P. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008, 274:13-17.
18. Mizuno T., Zhang G., Takeuchi H., Kawanokuchi J., Wang J., Sonobe Y., et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J 2008, 22:1797-1806.
19. Neumann H. Control of glial immune function by neurons. Glia 2001, 36:191-199.
20. Newcombe J., Uddin A., Dove R., Patel B., Turski L., Nishizawa Y., et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol Zurich Switz 2008, 18:52-61.
21. Noda H., Takeuchi H., Mizuno T., Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 2013, 256:13-18.
22. Norman E., Cutler R.G., Flannery R., Wang Y., Mattson M.P. Plasma membrane sphingomyelin hydrolysis increases hippocampal neuron excitability by sphingosine-1-phosphate mediated mechanisms. J Neurochem 2010, 114:430-439.
23. Paulus W., Classen J., Cohen L.G., Large C.H., Di Lazzaro V., Nitsche M., et al. State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimulat 2008, 1:151-163.
24. Piani D., Frei K., Do K.Q., Cuénod M., Fontana A. Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett 1991, 133:159-162.
25. Polazzi E., Contestabile A. Overactivation of LPS-stimulated microglial cells by co-cultured neurons or neuron-conditioned medium. J Neuroimmunol 2006, 172:104-111.
26. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.-P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
27. Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evid 2011, 6:13-21.
28. Reis J., Swayne O.B., Vandermeeren Y., Camus M., Dimyan M.A., Harris-Love M., et al. Contribution of transcranial magnetic stimulation to the understanding of cortical mechanisms involved in motor control. J Physiol 2008, 586:325-351.
29. Rossi S., Rossini P.M. TMS in cognitive plasticity and the potential for rehabilitation. Trends Cogn Sci 2004, 8:273-279.
30. Rossi S., Hallett M., Rossini P.M., Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009, 120:2008-2039.
31. Rossi S., Lo Giudice T., De Chiara V., Musella A., Studer V., Motta C., et al. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol 2012, 165:861-869.
32. Rossini P.M., Barker A.T., Berardelli A., Caramia M.D., Caruso G., Cracco R.Q., et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994, 91:79-92.
33. Sanger T.D., Garg R.R., Chen R. Interactions between two different inhibitory systems in the human motor cortex. J Physiol 2001, 530:307-317.
34. Sarchielli P., Greco L., Floridi A., Floridi A., Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 2003, 60:1082-1088.
35. Serpero L.D., Filaci G., Parodi A., Battaglia F., Kalli F., Brogi D., et al. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol 2013, 8:1106-1113.
36. Sim-Selley L.J., Goforth P.B., Mba M.U., Macdonald T.L., Lynch K.R., Milstien S., et al. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. J Neurochem 2009, 110:1191-1202.
37. Srinivasan R., Sailasuta N., Hurd R., Nelson S., Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain J Neurol 2005, 128:1016-1025.
38. Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005, 25:3219-3228.
39. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440:1054-1059.
40. Stover J.F., Pleines U.E., Morganti-Kossmann M.C., Kossmann T., Lowitzsch K., Kempski O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997, 27:1038-1043.
41. Tombini M., Pellegrino G., Pasqualetti P., Assenza G., Benvenga A., Fabrizio E., et al. Mobile phone emissions modulate brain excitability in patients with focal epilepsy. Brain Stimulat 2013, 6:448-454.
42. Vallejo-Illarramendi A., Domercq M., Pérez-Cerdá F., Ravid R., Matute C. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 2006, 21:154-164.
43. Vercellino M., Merola A., Piacentino C., Votta B., Capello E., Mancardi G.L., et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007, 66:732-739.
44. Vucic S., Burke T., Lenton K., Ramanathan S., Gomes L., Yannikas C., et al. Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 2012, 18:425-432.
45. Werner P., Pitt D., Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001, 50:169-180.
46. Zhang Y.H., Fehrenbacher J.C., Vasko M.R., Nicol G.D. Sphingosine-1-phosphate via activation of a G-protein-coupled receptor(s) enhances the excitability of rat sensory neurons. J Neurophysiol 2006, 96:1042-1052.
47. Ziemann U., Lönnecker S., Steinhoff B.J., Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996, 40:367-378.
48. Ziemann U., Rothwell J.C., Ridding M.C. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol 1996, 496:873-881.